Glaxosmithkline | GSK - Ordinary Share Capital


Glaxosmithkline reported GBP2.02B in Ordinary Share Capital for its fiscal quarter ending in September of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 608K Jun/2026
Amgen USD 541M 1000K Jun/2026
AstraZeneca USD 1.55B 28K Sep/2026
Aurora Cannabis CAD 63.31M 4.36M Jun/2026
Bausch Health Companies USD 374.25M 351K Sep/2026
Bristol-Myers Squibb USD 2.04B 7M Jun/2026
Canopy Growth CAD 422.07M 53.78M Mar/2026
Corcept Therapeutics USD 107.33M 1.36M Mar/2026
Drreddys Laboratories INR 833.07M 382K Sep/2026
Eli Lilly USD 943.5M 3.33M Mar/2026
GlaxoSmithKline GBP 2.02B 2.05B Sep/2026
Glaxosmithkline GBP 2.02B 2.03B Sep/2026
J&J USD 2.41B 1.64M Jun/2026
Merck USD 2.47B 1.05M Jun/2026
Novartis USD 1.89B 12.09M Sep/2026
Pacira USD 39.82M 512K Jun/2026
Perrigo USD 138.1M 500K Mar/2026
Pfizer USD 5.7B 0 Jun/2026
Phibro Animal Health USD 40.48M 0 Dec/2025
Prestige Brands USD 47.37M 53K Jun/2026
Roche Holding CHF 796.77M 1.15M Jun/2026
Sanofi EUR 1.2B 0 Sep/2026
Supernus Pharmaceuticals USD 58.16M 124K Jun/2026
Takeda JPY 1.58B 460K Jun/2026
Teva Pharmaceutical Industries USD 1.16B 1000K Jun/2026
Zoetis USD 414.15M 6.19M Jun/2026